The soon-to-be-approved injectible, T-20, has been hailed as the next big thing in salvage therapy. So imagine the dismay at news reports that in a University of Alabama study, the entry inhibitor caused rapid resistance. But a phone call to Alabama set the matter straight: It was a Phase I safety trial, and T-20 was tested alone -- a recipe for resistance. The good news is, scientists have now ID’d the first T-20 mutation.